KR20050034187A - Method of efficient surgical transfer of porcine nuclear transfer embryos - Google Patents
Method of efficient surgical transfer of porcine nuclear transfer embryos Download PDFInfo
- Publication number
- KR20050034187A KR20050034187A KR1020030070029A KR20030070029A KR20050034187A KR 20050034187 A KR20050034187 A KR 20050034187A KR 1020030070029 A KR1020030070029 A KR 1020030070029A KR 20030070029 A KR20030070029 A KR 20030070029A KR 20050034187 A KR20050034187 A KR 20050034187A
- Authority
- KR
- South Korea
- Prior art keywords
- ovulation
- cloned
- eggs
- transplanting
- ovary
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 210000002257 embryonic structure Anatomy 0.000 title description 8
- 238000012546 transfer Methods 0.000 title description 8
- 235000013601 eggs Nutrition 0.000 claims abstract description 86
- 230000016087 ovulation Effects 0.000 claims abstract description 44
- 210000001672 ovary Anatomy 0.000 claims abstract description 23
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 238000011161 development Methods 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 210000004246 corpus luteum Anatomy 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 241000282887 Suidae Species 0.000 abstract description 23
- 238000002054 transplantation Methods 0.000 abstract description 21
- 230000035935 pregnancy Effects 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 238000010367 cloning Methods 0.000 description 13
- 210000001082 somatic cell Anatomy 0.000 description 10
- 230000012173 estrus Effects 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 210000002459 blastocyst Anatomy 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 230000000392 somatic effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 2
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical class O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000010372 cloning stem cell Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0273—Cloned vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 돼지 복제란을 대리모돈에게 이식하는 방법에 관한 것으로서, 보다 상세하게는 1) 수정란 수송 키트에서 복제란을 배양하는 단계; 2) 펜토탈소디움과 아이소프란으로 대리모돈을 마취시키는 단계; 및 3) 배란직전 내지 배란 후 2일 이내의 난소를 가지는 대리모돈에게 단계 1의 복제란을 이식하는 단계를 포함하는 돼지 복제란을 대리모돈에게 이식하는 방법에 관한 것이다. 본 발명의 돼지 복제란의 이식 방법은 복제란의 이식에 있어서의 종래 문제점들을 개선하여 이식 후 임신효율을 높임으로써 복제돼지의 생산 효율을 증대시킬 수 있으며, 아울러 복제란 뿐만 아니라 일반 돼지수정란의 이식에도 응용되어 돼지의 생산효율을 증대시킬 수 있다.The present invention relates to a method for transplanting pig cloned eggs into surrogate sows, and more particularly, 1) culturing the cloned eggs in a fertilized egg transport kit; 2) anesthetizing surrogate with pentotalsodium and isofran; And 3) transplanting porcine cloned eggs into surrogate sows comprising the step of transplanting the cloned eggs of step 1 to surrogate sows having an ovary immediately before ovulation or within 2 days after ovulation. The method of transplanting pig cloned eggs of the present invention can improve the production efficiency of cloned pigs by improving the pregnancy problems after transplantation by improving the conventional problems in transplantation of cloned eggs, and also transplanting not only cloned eggs but also general pig fertilized eggs. It can also be applied to increase the production efficiency of pigs.
Description
본 발명은 돼지 복제란을 대리모돈에게 이식하는 방법에 관한 것으로서, 보다 상세하게는 복제란의 이식에 있어서의 종래 문제점들을 개선하여 이식 후 임신효율을 높임으로써 복제돼지의 생산 효율을 증대시킬 수 있는 돼지 복제란을 대리모돈에게 이식하는 방법에 관한 것이다.The present invention relates to a method of transplanting pig cloned eggs into surrogate sows, and more particularly, to improve the conventional problems in transplanting cloned eggs, thereby increasing the production efficiency of cloned pigs by increasing pregnancy efficiency after transplantation. A pig cloned egg relates to a method of transplanting the surrogate sows.
복제(cloning)는 유전적으로 동일한 개체를 만드는 것을 말하는데, 핵이식(nuclear transfer)은 진핵생물에 있어서의 복제의 한 방법으로 최근 분자생물학의 급격한 발달로 새로이 주목받게된 기술이다. 초기의 핵이식은 핵의 공급원으로 수정란의 할구를 이용하였으나(Prather, et al., Biol. Reprod., 1987, 37:856-866; Prather, et al., Biol. Reprod., 1989, 41:414-418), 최근에는 체세포의 핵을 이용하게 되었다.Cloning refers to the creation of genetically identical organisms. Nuclear transfer is a technique that has attracted new attention due to the recent rapid development of molecular biology as a method of cloning in eukaryotes. Nuclear transfer of early, but using the blastomeres of embryos as a source of nuclei (Prather, et al, B iol Reprod, 1987, 37:...... 856-866; Prather, et al, Biol Reprod, 1989, 41 : 414-418) Recently, somatic nuclei have been used.
체세포 복제는 분화된 체세포를 핵이 제거된 난자에 넣어 활성화시킨 다음에 일반 수정란과 동일한 방법으로 발생시키는 기술로서, 통상적으로 세포질을 흡입하여 난자의 핵을 제거하고 핵이 제거된 난자에 체세포를 주입한 후 전기적 자극을 가하여 난자-체세포 복합체를 융합 및 활성화시키는 단계를 포함한다. 이와 같은 복제기술은 발생생물학 분야를 비롯한 기초과학 분야의 연구에 널리 이용될 수 있을 뿐만 아니라 유용 단백질의 생산, 질환 모델의 개발 및 장기 이식 분야 등 다양한 의학 및 의약 분야에 크게 기여할 것으로 예상되어 그 산업적 이용성이 매우 크다고 할 수 있다.Somatic cloning is a technique in which differentiated somatic cells are inserted into a nucleus from which the nucleus has been removed and activated, and then generated in the same manner as a normal fertilized egg. In general, inhalation of the cytoplasm removes the nucleus of an egg and implants somatic cells into the nucleus from which the nucleus has been removed. And then applying electrical stimulation to fuse and activate the oocyte-somatic complex. Such cloning technology can be widely used in research in basic sciences including developmental biology, and is expected to contribute greatly to various medical and pharmaceutical fields such as production of useful proteins, development of disease models, and transplantation of organs. It can be said that the availability is very large.
돼지의 수정란 이식은 우수한 품종의 돼지를 단기간 내에 대량으로 공급함으로써 돼지의 번식효율을 높이기 위하여 개발되었는데, 최근 복제 및 형질전환을 통한 고가의 치료용단백질 생산 및 대체장기의 대상 동물로 돼지가 부상하면서 돼지 복제란의 이식에 대한 관심이 높아지고 있다.The fertilized egg transplantation of pigs was developed to improve the breeding efficiency of pigs by supplying large quantities of excellent breed pigs in a short period of time. Recently, as pigs emerged as target animals for the production of expensive therapeutic proteins and replacement organs through cloning and transformation, There is a growing interest in the transplantation of porcine cloned eggs.
최초의 체세포 복제 동물인 돌리(Willmut, I. et al., Nature, 1997, 385:810-813)가 탄생한 이후, 체세포 복제 분야는 많은 발전을 거듭하여 소(Cibelli, JB. et al., Science, 1998, 280:1256-1258; Wells, DN. et al., Reprod. Fertil. Dev., 1998, 10:369-378), 생쥐(Wakayama, T. et al., Nature, 1998, 394:369-374), 산양(Bagusi, A. et al., Nat. Biotechnol., 1999, 17:456-461) 등의 복제에 성공하게 되었다. 그러나, 돼지는 다른 종에 비하여 수정란에 대한 연구가 상대적으로 적게 이루어졌고, 최소한 4마리의 태아가 자궁에 착상해야만 임신이 유지되는 생리적 특성 등 여러 가지 어려움 때문에 주요 가축 중에서는 비교적 늦게 복제에 성공을 하게 되었다(Poleajaeva, IA. et al., Nature, 2000, 407:86-90; Onishi, A. et al., Science, 2000, 289:1188-1190; Betthauser, J. et al., Nat. Biotechnol., 2000, 18:1055-1059). 그 후, 돼지 체세포에 외부 유전자를 주입시켜 복제에 성공함으로써 최초의 형질전환 복제 돼지가 탄생하였고(Park, KW. et al., Anim. Biotechnol., 2001, 12:173-181), 특정유전자를 체세포에서 결손(knockout)시킨 복제 돼지도 성공하였다(Lai, L. et al., Nat. Biotechnol., 2002 Mar, 20(3):251-255). 그러나, 돼지 체세포 복제 분야의 급속한 발전에도 불구하고 아직도 복제의 효율은 1-5%로 낮으며, 또한 임신기의 태아의 폐사, 태아가 비정상적으로 커지는 산자비대증 등과 같은 출산 후 나타나는 여러 가지 건강상 및 신체적 이상이 보고된 바 있어(Cibelli JB. et al., Science, 1998, 280:1256-1258; Hill JR et al., Theriogenology, 1999, 51:1451-1465; Carter DB et al., Cloning Stem Cells, 2002, 4:131-145; Park KW et al., Biol. Reprod., 2002, 66:1001-1005) 복제의 효율을 개선시키기 위한 많은 연구가 요구되고 있다.Since the birth of the first somatic cloning animal, Dollmut (I. et al., Nature , 1997, 385: 810-813), the field of somatic cloning has evolved a great deal (Cibelli, JB. Et al., Science , 1998, 280: 1256-1258; Wells, DN. Et al., Reprod.Fertil. Dev ., 1998, 10: 369-378), mice (Wakayama, T. et al., Nature , 1998, 394: 369-374), goats (Bagusi, A. et al., Nat. Biotechnol ., 1999, 17: 456-461) have been successfully cloned. However, compared to other species, pigs have been relatively poorly studied in fertilized eggs, and due to various difficulties, such as physiological characteristics in which at least four fetuses are implanted in the uterus to maintain pregnancy, the pigs have been successfully replicated relatively late among major livestock. (Poleajaeva, IA. Et al., Nature , 2000, 407: 86-90; Onishi, A. et al., Science , 2000, 289: 1188-1190; Betthauser, J. et al., Nat. Biotechnol , 2000, 18: 1055-1059). Subsequently, the first successful transgenic cloned pig was born by injecting an external gene into pig somatic cells (Park, KW. Et al., Anim. Biotechnol ., 2001, 12: 173-181). Cloned pigs knocked out in somatic cells were also successful (Lai, L. et al., Nat. Biotechnol. , 2002 Mar, 20 (3): 251-255). However, despite the rapid development of the porcine somatic cloning field, the efficiency of cloning is still low at 1-5%, and also various health and physical symptoms after childbirth, such as mortality of the fetus in pregnancy and maternal hypertrophy of the fetus. Abnormalities have been reported (Cibelli JB. Et al., Science , 1998, 280: 1256-1258; Hill JR et al., Theriogenology , 1999, 51: 1451-1465; Carter DB et al., Cloning Stem Cells , 2002, 4: 131-145; Park KW et al., Biol. Reprod. , 2002, 66: 1001-1005) Many studies are needed to improve the efficiency of replication.
한편, 돼지의 체세포 복제에 있어서 복제란의 이식 적기에 대한 연구는 많이 수행되어 있지 않다. 현재, 대부분의 연구자들은 돼지 복제란을 제조한 후 1-2일 이내에 대리모돈에 이식하고 있으나, 이식에 적합한 여러 가지 조건에 대한 연구는 미미한 실정이다.On the other hand, studies on the timely transplantation of cloned eggs in somatic cell cloning of pigs have not been carried out. Currently, most researchers are transplanting to surrogate sows within 1-2 days after the production of cloned pigs, but the study of various conditions suitable for transplantation is insignificant.
이에, 본 발명자들은 상기와 같은 복제 돼지 제조에 있어서의 문제점을 해결하기 위하여, 복제돼지의 생산에 있어서 복제란의 수송, 복제란 이식적기의 선정 및 외과적 수술 등을 검토하여 복제돼지의 생산 효율을 증진하기 위하여 노력한 결과 최적의 돼지 복제란 이식 조건을 확립함으로써 본 발명을 완성하였다.In order to solve the above problems in the production of cloned pigs, the present inventors have examined the transport of cloned eggs, selection of cloned egg transplanters, and surgical operations in the production of cloned pigs. Efforts have been made to improve the results of the present invention by establishing optimal pig cloning transplant conditions.
본 발명의 목적은 돼지 복제란을 대리모돈에게 이식하는 최적의 이식 방법을 제공하는 것이다. It is an object of the present invention to provide an optimal transplantation method for transplanting pig cloned eggs into surrogate sows.
상기 목적을 달성하기 위하여, 본 발명은 In order to achieve the above object, the present invention
1) 수정란 수송 키트에서 복제란을 배양하는 단계;1) culturing the cloned eggs in a fertilized egg transport kit;
2) 펜토탈소디움과 아이소프란으로 대리모돈을 마취시키는 단계; 및2) anesthetizing surrogate with pentotalsodium and isofran; And
3) 배란직전 내지 배란 후 2일 이내의 난소를 가지는 대리모돈에게 단계 1의 복제란을 이식하는 단계를 포함하는 돼지 복제란을 대리모돈에게 이식하는 방법을 제공한다.3) Provided is a method for transplanting pig cloned eggs into surrogate sows comprising the step of transplanting the cloned eggs of step 1 to surrogate sows having an ovary immediately before ovulation or within 2 days after ovulation.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
상기 목적을 달성하기 위하여, 본 발명은 In order to achieve the above object, the present invention
1) 수정란 수송 키트에서 복제란을 배양하는 단계;1) culturing the cloned eggs in a fertilized egg transport kit;
2) 펜토탈소디움과 아이소프란으로 대리모돈을 마취시키는 단계; 및2) anesthetizing surrogate with pentotalsodium and isofran; And
3) 배란직전 내지 배란 후 2일 이내의 난소를 가지는 대리모돈에게 단계 1의 복제란을 이식하는 단계를 포함하는 돼지 복제란을 대리모돈에게 이식하는 방법을 제공한다.3) Provided is a method for transplanting pig cloned eggs into surrogate sows comprising the step of transplanting the cloned eggs of step 1 to surrogate sows having an ovary immediately before ovulation or within 2 days after ovulation.
상기에서, 단계 1의 복제란의 배양 시간은 5시간 이내인 것이 바람직하다.In the above, the incubation time of the cloned eggs of step 1 is preferably within 5 hours.
또한, 단계 2의 펜토탈소디움의 투여량은 1.0 내지 2.0 g인 것이 바람직하고, 1.5 g인 것이 더욱 바람직하며, 아이소프란은 2 내지 5%의 아이소프란을 5% 산소와 함께 흡입시키는 것이 바람직하다.In addition, the dose of pentotalsodium in step 2 is preferably 1.0 to 2.0 g, more preferably 1.5 g, and isopran preferably inhales 2 to 5% of isopran with 5% oxygen. .
단계 3에 있어서, 난소는 배란점의 배란경과 시간에 따라 3단계로 구분하였으며, 배란 직전이어서 난포가 비대해져 있거나 배란이 되어 배란부위가 크며 붉게 충혈되어 있는 난소(OD0 단계), 배란이 경과하여 배란점 부위가 조금 아물었지만 아직 붉게 출혈되어 있고 배란점이 거의 아문상태의 난소(OD1 단계) 및 배란점이 아물고 황체가 조금 발달하여 비대해져 있으며 유두모양을 하고 있는 난소(OD2 단계)로 구성된 군으로부터 선택되는 것이 바람직하다.In stage 3, the ovary was divided into three stages according to the ovulation time and time of ovulation, the follicle was enlarged immediately before ovulation, or the ovulation was large and the reddish ovary (OD0 stage) and ovulation had passed. It is selected from the group consisting of ovary (OD1 stage) with bleeding point and ulceration point, ovary with ovulation point and ovary with a little development of luteal mass, and papillary ovary (OD2 stage). desirable.
본 발명에서는 복제돼지의 생산에 있어서 복제란의 원거리 수송, 복제란 이식 적기의 검토 및 외과적 수술 등의 과정을 개선하여 복제란의 이식효율 및 복제돼지의 생산 효율을 증진시켰다.In the present invention, in the production of cloned pigs, the process of remote transfer of cloned eggs, timely review of cloned egg transplantation time, and surgical operations were improved to enhance the transfer efficiency of cloned eggs and the production efficiency of cloned pigs.
복제란은 비교적 약하기 때문에 대리모돈에 이식할 때는 배양기에서 꺼내 단시간 내에 이식하는 것이 바람직하다. 이식시설이 실험실 근처에 있을 때는 문제가 되지 않지만 여러 사정에 의하여 농장까지 이동할 필요가 있을 때는 복제란을 이식장소까지 수송하는 과정에서 수정란에 해를 줄 가능성이 높으며, 또한 복제란이 해를 입으면 대리모돈에서 착상이 어려워지고 착상 후에도 태아 발생이 제대로 되지 않을 수 있다. 본 발명에서는 상기와 같은 문제를 해결하기 위하여 수정란 수송 키트(embryo transport kit, Mititub, 독일)를 이용하였다. 본 발명의 수정란 수송 키트는 35℃ 내지 42℃의 온도를 지정해 놓아 일정기간 동안 온도를 유지하게 하는 장치이며, 원통형의 보관통과 이 보관통의 온도를 유지시켜 주기 위한 충전기로 이루어져 있다. 본 발명에서 복제란을 상기 키트에서 5시간 배양하고 다시 일반 배양기에서 배양한 결과 복제란의 체외발생은 대조군과 큰 차이를 보이지 않았다(표 1 참조). 상기 결과는 수정란 수송 키트를 이용하여 5시간 이내에 복제란을 수송하는 것이 복제란의 체외발생에 지장을 주지 않는다는 것을 시사한다.Since the cloned eggs are relatively weak, it is preferable to remove them from the incubator in a short time when transplanting them into surrogate sows. This is not a problem when the transplant is near the laboratory, but when it is necessary to move to the farm due to various circumstances, it is highly likely to harm the fertilized eggs in the process of transporting the cloned eggs to the transplant site. It can be hard to implant in your money, and even after implantation, the fetus may not develop properly. In the present invention, in order to solve the above problems, an embryo transport kit (embryo transport kit, Mititub, Germany) was used. The fertilized egg transport kit of the present invention is a device for maintaining a temperature for a predetermined period of time by specifying a temperature of 35 ℃ to 42 ℃, consisting of a cylindrical reservoir and a charger for maintaining the temperature of the reservoir. In the present invention, the cloned eggs were incubated in the kit for 5 hours and again cultured in a general incubator, and in vitro development of the cloned eggs did not show a significant difference from the control group (see Table 1). The results suggest that transporting cloned eggs within 5 hours using the fertilized egg transport kit does not interfere with in vitro development of the cloned eggs.
돼지의 수정란 이식은 많은 발전을 거듭하여 최근에는 복제수정란을 이식하여 복제돼지의 생산이 가능하게 되었다. 그러나 대리모돈에서 어느 시기가 이식 적기인지에 대해서는 명확하게 알려진 바가 없으며, 현재 대부분의 연구자들은 복제란을 만든 당일 또는 1일 이내에 대리모돈에 이식을 하고 있다. 대리모돈의 선정에 있어서는 발정을 기준으로 이식하고 있지만, 발정 지속 시간이 12-96 시간으로 그 범위가 넓기 때문에 이식적기의 기준은 발정보다는 난소의 배란점 상태를 보고 판단하는 것이 더 적합할 것이다. 따라서, 본 발명에서는 배란점의 상태에 따라 난소를 OD0, OD1 및 OD2의 3단계로 구분한 후 실험을 실시하였다(도 1 참조). 상기에서 OD0는 배란 전후, OD1은 배란 후 배란점이 아무는 시기, OD2는 배란점이 완전히 아물었으며 비대해진 시기를 나타낸다. 그 결과, OD0에서 2마리, OD1과 OD2에서 각각 1마리씩 초기 임신(임신 30일)이 확인되었고 OD1은 임신 64일 퇴행하고 나머지 3 두는 임신 114일에 제왕절개 수술로 11두의 새끼가 태어났다 (표2 참조). 이와 같은 사실은 1-2 일째 된 복제란을 이식할 때는 발정 1일째 대리모돈이 이식에 적합하며, 난소의 상태를 기준으로 할 때는 배란 전후에 이식하는 것이 임신율을 높일 수 있다는 것을 나타낸다.Pig embryo transplantation has been developed a lot, and recently, it has been possible to produce cloned pigs by transplanting cloned fertilized eggs. However, it is not clear at what time of day the transplant is time for surrogate sow, and most researchers now transplant to surrogate sows on the day or within the day of cloning. In the selection of surrogate sows, transplantation is based on estrus, but since the duration of estrus ranges from 12 to 96 hours, it may be more appropriate to determine the ovarian ovulation status rather than estrus. Therefore, in the present invention, the experiment was performed after dividing the ovary into three stages of OD0, OD1 and OD2 according to the state of ovulation point (see FIG. 1). In the above, OD0 is before and after ovulation, OD1 is when the ovulation point is any after ovulation, and OD2 is when the ovulation point is completely healed, and it indicates the time of bloat. As a result, the initial pregnancy (30 days of pregnancy) was confirmed, 2 in OD0 and 1 in OD1 and OD2 respectively, and OD1 regressed 64 days in pregnancy and the other three had cesarean section at 114 days of pregnancy. (See Table 2). This fact indicates that surrogate sows are suitable for transplantation on day 1 of estrus when transplanting 1-2 days old cloned eggs, and implantation before and after ovulation may increase pregnancy rates based on ovarian status.
또한, 본 발명에서는 대리모돈을 마취할 때 펜토탈소디움과 아이소프란을 이용하였다. 펜토탈소디움은 1935년 Volwiler와 Jabern이 합성한 티오바비투릭산(thiobarbituric acid)계 화합물 중의 하나이며, 초단시간형의 마취제로서 중추신경계의 뇌간 망상체부활계를 가역적으로 억제함으로써 진정, 수면작용 및 마취작용을 나타낸다. 펜토탈소디움을 귀정맥에 투여하면 대리모돈은 1분 내에 정신을 잃고 쓰러지는데, 수분이 경과하면 서서히 깨기 시작하므로 가급적 단시간에 2-5% 아이소프란을 5% 산소와 함께 흡입시켜야한다. 상기와 같은 마취방법을 이용하게 되면 돼지를 쉽게 마취시킬 수 있으며, 수술 중에 돼지가 깨는 일이 없어 돼지에게 고통을 덜 수 있다. 수술이 끝나고 아이소프란의 공급이 차단되면 돼지는 수분 내에 의식을 회복하고 30-60분 안에 서서 걸을 수 있다. 이와 같은 사실은 상기와 같은 마취방법이 돼지에 스트레스를 덜 주는 방법이라고 할 수 있다. 이러한 마취방법은 돼지의 수술에 있어서 전반적으로 응용이 가능하며, 특히 복제란 이식과 같이 수술 후 돼지에서 산자를 얻을 목적이 있을 경우에는 이와 같은 마취법이 절실할 것이다.In the present invention, pentotal sodium and isopran were used to anesthetize surrogate sows. Pentotalsodium is one of the thiobarbituric acid compounds synthesized by Volwiler and Jabern in 1935. It is an ultrashort type of anesthetic and it relieves sedation, sleep and anesthesia by reversibly inhibiting the brain stem rehabilitation system of the central nervous system. Action. When pentotalsodium is administered to the ear vein, the surrogate sows lose their mind in one minute and fall down, and after a few minutes they start to wake up slowly, so you should inhale 2-5% isofran with 5% oxygen in the shortest possible time. Using the anesthesia method as described above can easily anesthetize the pig, and the pig does not break during the operation can be less pain to the pig. After the operation is over and the supply of isopran is cut off, the pig can recover from consciousness in minutes and walk within 30-60 minutes. This fact can be said that the method of anesthesia is less stress on the pig. This anesthesia method is generally applicable in the operation of pigs, especially if the purpose of obtaining live in pigs after surgery, such as cloning egg transplantation will be desperately needed.
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.
<실시예 1> 돼지 체세포를 이용한 복제란의 제조Example 1 Preparation of Cloned Egg Using Porcine Somatic Cells
<1-1> 돼지 체세포의 분리<1-1> Isolation of Porcine Somatic Cells
임신 35일령의 돼지 태아를 면도날로 잘게 자른 후, 세포를 트립신-EDTA (Gibco. Inc)가 첨가된 DMEM 배지(bio-whittaka. Inc)에서 5분간 배양하였다. 상층액을 원심분리(1,000 rpm, 5분)한 후 10% FCS(Fetal Calf Serum, Hyclone. Inc)가 포함된 DMEM 배지에서 배양하고 세포가 90% 포화상태(confluency)에 이르면 트립신을 처리하여 계대배양하였으며, 이들 중 일부는 핵이식에 이용하고 나머지는 동결보존하였다.After gestation of a 35-day-old pig fetus with a razor blade, the cells were incubated for 5 minutes in DMEM medium (bio-whittaka. Inc) to which trypsin-EDTA (Gibco. Inc) was added. The supernatant was centrifuged (1,000 rpm, 5 min), incubated in DMEM medium containing 10% Fecal Calum Serum (Hyclone. Inc), and passaged after trypsin treatment when the cells reached 90% confluency. Some of them were used for nuclear transfer and others were cryopreserved.
<1-2> 난자 채취 및 배양<1-2> Oocyte Collection and Culture
도축장에서 미경산돈의 난소를 채취하여 35 내지 39℃, 0.9% 생리적 식염수에 보관하였다. 10 ㎖ 주사기에 18 게이지 바늘을 연결하여 상기 난소의 직경 2 내지 6 ㎜ 난포에서 난포액을 흡입하여 난자를 채취하였다. 상기 난자를 성숙배양액에서 세척하고, 500 ㎕ 배양액에 50 내지 60개의 난자를 넣어 42 내지 46시간 동안 배양하였다.Ovaries of unpolished pigs were collected from slaughterhouses and stored in 35-39 ° C. and 0.9% physiological saline. An egg was collected by attaching an 18 gauge needle to a 10 ml syringe and sucking the follicular fluid from the follicle of 2 to 6 mm in diameter. The eggs were washed in mature culture medium, and 50 to 60 eggs were added to 500 µl culture and incubated for 42 to 46 hours.
이때, 상기 성숙 배양액은 TCM 199 (31100035; Gibco, Grand Island, NY)에 0.1% 폴리비닐알콜(polyvinyalcohol), 3.05 mM 포도당(D-glucose), 0.91 mM 소듐피루베이트(sodium pyruvate), 0.57 mM 시스테인(cysteine), 0.5 ㎍/㎖ LH(Sigma Chemical Co. St. Louis, MO), 0.5 ㎍/㎖ FSH(Sigma), 10 ng/㎖ 상피성장인자(epidermal growth factor, Sigma), 75 ㎍/㎖ 페니실린 G 및 50 ㎍/㎖ 스트렙토마이신을 첨가하여 제조되었다.At this time, the mature culture medium in TCM 199 (31100035; Gibco, Grand Island, NY) 0.1% polyvinyl alcohol (polyvinyalcohol), 3.05 mM glucose (D-glucose), 0.91 mM sodium pyruvate, 0.57 mM cysteine (cysteine), 0.5 μg / ml LH (Sigma Chemical Co. St. Louis, MO), 0.5 μg / ml FSH (Sigma), 10 ng / ml epidermal growth factor (Sigma), 75 μg / ml penicillin Prepared by adding G and 50 μg / ml streptomycin.
<1-3> 미세조작(micromanipulation)<1-3> micromanipulation
실시예 <1-2>에서 채취된 난자를 미세조작용 배양액에서 5 내지 10 분간 배양한 후, 실시예 <1-1>에서 분리된 돼지 체세포를 상기 배양액에 첨가하였다. 이때, 미세조작용 배양액은 TCM 199에 0.3% BSA 및 7.5 ㎍/㎖ CB(cytochalasin B)를 첨가하여 제조되었다.After culturing the oocytes harvested in Example <1-2> for 5 to 10 minutes in a microalgae culture solution, the porcine somatic cells isolated in Example <1-1> were added to the culture solution. At this time, the microalgae culture was prepared by adding 0.3% BSA and 7.5 μg / ml CB (cytochalasin B) to TCM 199.
난자의 핵을 제거하기 위하여, 선단이 30 내지 60°로 날카롭게 연마된 직경 30 ㎛의 미세유리관을 준비하였다. 먼저 난자의 극체를 1시 방향으로 고정시키고, 상기 미세유리관을 극체가 있는 방향으로 찔러 넣었다. 유압을 이용하여 극체와 극체 주위의 세포질을 약 10-20% 정도 흡입하였으며, 대부분의 핵은 극체 주위에 위치해 있으므로 상기 과정에서 대부분의 난자의 핵이 제거되었다. 그 후에 상기 미세유리관을 이용하여 실시예 2에서 제조된 돼지 체세포를 흡입하고 상기 미세유리관을 핵이 제거된 난자의 위란강에 위치시킨 후 유압을 이용하여 체세포를 난자의 위란강에 주입시켰다.In order to remove the nucleus of an egg, a 30 micrometer diameter microglass tube whose tip was sharply ground to 30-60 degrees was prepared. First, the pole body of the egg was fixed at 1 o'clock, and the microglass tube was inserted into the pole body. Hydraulic pressure was used to inhale about 10-20% of the pole body and the cytoplasm around the pole. Since most of the nuclei are located around the pole, most of the nuclei of the eggs were removed. Thereafter, the porcine somatic cells prepared in Example 2 were sucked using the microglass tube, and the microglass tube was placed in the gastric cavity of the egg from which the nucleus was removed, and the somatic cells were injected into the gastric cavity of the egg using hydraulic pressure.
<1-4> 세포융합 및 활성화<1-4> Cell fusion and activation
실시예 <1-3>의 미세조작이 끝나면 핵이식란을 활성화 배양액에 넣은 후 간격이 1 ㎜ 떨어진 백금 전기선 사이에 난자-체세포 복합체를 위치시키고, 융합기(BTX Electro-Cell Manipulation 2001)로 1.1 ㎸/㎝, 30 ㎲의 DC 펄스를 2회 가하여 세포융합 및 활성화를 유도하였다. 전기 자극을 가한 후 0.5 내지 1시간 후에 융합률을 검사하였다. 상기 활성화 배양액은 0.3 M 만니톨(mannitol)에 1 mM CaCl2ㆍH2O, 0.1 mM MgCl2ㆍ6H2O 및 0.5M HEPES 완충액을 첨가하여 제조되었다.After the micromanipulation of Example <1-3>, the nuclear transfer embryos were placed in the activated culture medium, and the egg-somatic cell complexes were placed between the platinum electric wires spaced 1 mm apart, and then subjected to 1.1 ㎸ with a fusion machine (BTX Electro-Cell Manipulation 2001). DC pulse of 30 cm / cm / cm was added twice to induce cell fusion and activation. The fusion rate was checked 0.5 to 1 hour after the electrical stimulation was applied. The activated culture was prepared by adding 1 mM CaCl 2 .H 2 O, 0.1 mM MgCl 2 .6H 2 O, and 0.5M HEPES buffer to 0.3 M mannitol.
<1-5> 복제란의 배양 및 발생<1-5> Cultivation and development of cloned eggs
실시예 <1-4>에서 제조된 융합 복제란을 선별한 후, 500 ㎕의 발생 배양액이 들어 있는 4-웰 용기에서 20 내지 30개의 복제란을 6일동안 배양하였다. 배양완료 후에 5 ㎍/㎖의 헥스트 33342로 염색하고, 형광현미경 하에서 핵수를 검사하였다. 상기 발생 배양액은 NCSU-23(북캐롤리나주립대-23; Petters, RM. and Wells, KD., J. Reprod. Fertil. Suppl., 1993, 48:61-73) 배지에 0.4% BSA를 첨가하여 제조되었다.After selecting the fused cloned eggs prepared in Example <1-4>, 20-30 cloned eggs were incubated for 6 days in a 4-well container containing 500 μl of the developing culture solution. After completion of the culture, 5 μg / ml of hex 33342 was stained and the number of nuclei was examined under a fluorescence microscope. The development culture was prepared by adding 0.4% BSA to NCSU-23 (Northern Carolina State University-23; Petters, RM. And Wells, KD., J. Reprod. Fertil. Suppl. , 1993, 48: 61-73) medium. It became.
<실시예 2> 최적의 복제란 이식 조건의 확립Example 2 Establishment of Optimal Cloning Embryos Transplantation Conditions
<2-1> 복제란의 운반<2-1> Transport of cloned eggs
복제란을 수정란수송 키트에 보관하는 것이 복제란의 체외발달에 미치는 영향에 대하여 검토하였다. 이를 위하여, 본 발명자들은 상기 실시예 1에서 제조된 복제란을 이식하는 날 아침에 발생배양액이 들어 있는 튜브로 옮긴 후 이것을 수정란수송 키트 (embryo transport kit, Minitube)에 넣어 이식 시설까지 운반하였다. 이때, 키트내의 온도는 38.5??를 유지시켰으며 복제란을 제작한 당일 날 수송키트에 보관한 것을 D0, 복제란을 제작하고 1일간 배양 후 수송키트에 보관한 것을 D1, 2일째 수송키트에 보관한 것을 D2라고 하였다. 복제란은 키트에서 5시간 동안 보관 후 다시 배양기에서 배반포기까지 배양하였으며, 복제란을 제조하고 수정란수송 키트에서 배양하지 않은 것을 대조군으로 하였다.The effects of storage of cloned eggs in fertilized egg transport kit on in vitro development of cloned eggs were examined. To this end, the present inventors transferred the cloned eggs prepared in Example 1 to the tube containing the embryo culture on the morning of transplanting, and then put them in a fertilized egg transport kit (embryo transport kit, Minitube) to transport to the transplant facility. At this time, the temperature in the kit was maintained at 38.5 ?? and the D0 stored in the transport kit on the day of making the cloned eggs, the cloned eggs were made and stored in the transport kit for 1 day in the transport kit on the D1, 2nd day. The stored thing was called D2. The cloned eggs were stored in the kit for 5 hours and then cultured again from the incubator to the blastocyst. As a control, the cloned eggs were prepared and not cultured in the fertilized egg transport kit.
<2-2> 복제란의 외과적 이식<2-2> Surgical Transplantation of Cloned Eggs
매일 아침마다 돼지의 외음부를 관찰하여 충혈이 되고 부어오르며 등 뒤에서 타면 가만히 있는 개체를 발정이 온 것으로 추정하였으며, 이 돼지에 웅돈을 접촉시켰을 때 피하지 않고 웅돈에 붙는 것을 발정이 온 것으로 간주하였다. 복제란의 이식은 발정이 온 다음날에 실시하였다.Every morning, the vulva of the pig was observed to be red, swollen, and burned from the back. It was estimated that the estrus had come to heat, and when the pig was in contact with it, it was considered that the estrus had not avoided. The embryos were transplanted the day after estrus.
돼지의 위턱을 끈으로 고정하고 한쪽 귀에 고무 밴드를 채워 혈액의 흐름을 막은 후 바늘을 정맥에 찔러 넣었다. 혈액이 바늘을 통해 흘러나오기 시작하면 바늘에 주사기를 연결하고 팬토탈소디움(중외제약) 1.5 g을 30 ㎖ 주사용 증류수에 용해시켜 주사하였다. 돼지를 수술대에 올려놓고 코에 흡입 마취기를 연결한 후 2-5% 아이소프란(중외제약)을 흡입시켰다. 돼지의 하복부의 털을 털깎기 기계로 제거하고 베타딘과 알코올로 소독하였다. 상기 실시예 <2-1>에서 운반한 복제란 100-200개를 0.4% BSA가 포함된 NCSU23 배양액에 준비하고 카테터 (Tom Cat Catheter, Sherwood, USA)에 1 ㎖ 주사기를 연결하여 복제란을 흡입한 후 카테터를 난관에 삽입하고 복제란을 주입하였다. 수술이 끝나면 대리모돈을 돈방에 넣고 회복할 때가지 점검하였다. 대리모돈에 복제란을 이식한 후 35일째 되는 날 초음파 진단기(Mysono 201, Medison Co. Korea)로 임신 여부를 검사하였다.The upper jaw of the pig was fixed with a string, and a rubber band was filled in one ear to block the flow of blood, and then a needle was inserted into the vein. When blood began to flow through the needle, a syringe was connected to the needle, and 1.5 g of Pantotalsodium (Supplied Pharmaceuticals) was dissolved in 30 ml of distilled water for injection. The pigs were placed on the operating table, connected with an inhalation anesthesia in the nose, and then inhaled 2-5% isopran. The pig's lower abdomen hair was removed with a shearing machine and sterilized with betadine and alcohol. 100-200 cloned eggs transported in Example <2-1> were prepared in NCSU23 culture solution containing 0.4% BSA, and 1 mL syringes were connected to a catheter (Tom Cat Catheter, Sherwood, USA) to inhale the cloned eggs. The catheter was then inserted into the fallopian tube and cloned eggs were injected. After the operation, the surrogate sows were placed in the pig room and checked until recovery. On day 35 after the cloned embryos were transplanted into surrogate sows, pregnancy was examined using an ultrasound diagnostic device (Mysono 201, Medison Co. Korea).
그 결과, 처리군의 분할율 및 배반포 발생률은 각각 60.1-64.6% 및 7.3-13.6%로 나타나 대조군의 64.6% 및 12.3%와 서로 유의한 차이를 보이지 않음을 확인하였다. 배반포의 세포수도 18.4-22.5개로 나타나 대조군의 21.2개와 차이를 보이지 않았다(표 1).As a result, the splitting rate and blastocyst incidence rate of the treatment group were 60.1-64.6% and 7.3-13.6%, respectively, which showed no significant difference from 64.6% and 12.3% of the control group. The number of blastocysts was also 18.4-22.5, showing no difference from 21.2 of the control group (Table 1).
상기 표 1에서,In Table 1 above,
을 나타낸다. Indicates.
또한, 본 발명자들은 난소에서 배란점을 확인하고 배란 후 경과한 시간 및 난소의 형태에 따라 3가지 형태로 분류하였다. 배란직전이어서 난포가 비대하여 있거나 배란이 되어 배란부위가 크며 붉게 충혈 되어 있는 단계를 OD(ovulation day) 0로 하였다. 배란이 경과하여 배란점 부위가 조금 아물었지만 아직 붉게 충혈 되어 있고 배란점이 거의 아문상태를 OD1로 하고, 배란점이 아물고 황체가 조금 발달하여 비대해져 있으며 유두모양을 한 단계를 OD2로 하였다(도 1). 그 결과, 대리모돈 14마리에 복제란을 이식하여 4마리의 임신을 얻었다. 난소에 따라서는 OD0가 2마리 OD1과 OD2가 각각 1마리였다(표 2).In addition, the inventors identified the ovulation point in the ovary and classified into three types according to the time elapsed after ovulation and the shape of the ovary. Immediately before ovulation, the follicle was enlarged or ovulated, and the ovulation site was large and reddish. Ovulation progressed, the ovulation site was slightly healed, but red blood redness and ovulation was almost hyperused to OD1, the ovulation point was closed and the corpus luteum developed a little, and the papillary shape was OD2 (Fig. 1). As a result, cloned eggs were transplanted into 14 surrogate sows and 4 pregnant women were obtained. Depending on the ovary, two OD0 animals were found, one OD1 and one OD2 (Table 2).
경과 일수 : 복제란을 제조하여 이식할 때까지 체외배양한 일 수Days elapsed: Number of days of in vitro culture from cloned eggs to transplantation
상기에서 살펴본 바와 같이, 본 발명의 돼지 복제란의 이식 방법은 복제란의 이식에 있어서의 종래 문제점들을 개선하여 이식 후 임신효율을 높임으로써 복제돼지의 생산 효율을 증대시킬 수 있으며, 아울러 복제란 뿐만 아니라 일반 돼지수정란의 이식에도 응용되어 돼지의 생산효율을 증대시킬 수 있다.As described above, the method of transplanting pig cloned eggs of the present invention can improve the production efficiency of cloned pigs by improving the pregnancy efficiency after transplantation by improving the conventional problems in transplantation of cloned eggs, as well as cloned eggs. In addition, it can be applied to the transplantation of common pig fertilized eggs can increase the production efficiency of pigs.
도 1은 배란 후 경과에 따른 난소의 분류를 보여주는 사진으로서, 배란직전이어서 난포가 비대하여 있거나 배란이 되어 배란부위가 크며 붉게 충혈 되어 있는 단계의 난소(A, OD0), 배란이 경과하여 배란점 부위가 조금 아물었지만 아직 붉게 충혈되어 있고 배란점이 거의 아문상태의 난소(B, OD1) 및 배란점이 아물고 황체가 조금 발달하여 비대해져 있으며 유두모양을 한 단계의 난소(C, OD2)를 나타낸다. Figure 1 is a picture showing the classification of ovary according to the ovulation after ovulation, the ovary (A, OD0) in the stage of ovulation is large and red erythema due to ovarian hypertrophy or ovulation, just before ovulation, ovulation point The site is slightly healed, but it is still red, and the ovulation point is almost hypertrophic ovary (B, OD1) and the ovulation point is closed, and the corpus luteum develops a little and is enlarged, and the papilla-like ovary (C, OD2) is shown.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030070029A KR20050034187A (en) | 2003-10-08 | 2003-10-08 | Method of efficient surgical transfer of porcine nuclear transfer embryos |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030070029A KR20050034187A (en) | 2003-10-08 | 2003-10-08 | Method of efficient surgical transfer of porcine nuclear transfer embryos |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20050034187A true KR20050034187A (en) | 2005-04-14 |
Family
ID=37238102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030070029A KR20050034187A (en) | 2003-10-08 | 2003-10-08 | Method of efficient surgical transfer of porcine nuclear transfer embryos |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20050034187A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100807644B1 (en) * | 2007-03-19 | 2008-02-28 | 충남대학교산학협력단 | Piglet production method by simultaneous transfer of embryos formed by in vitro fertilization and nuclear transfer |
-
2003
- 2003-10-08 KR KR1020030070029A patent/KR20050034187A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100807644B1 (en) * | 2007-03-19 | 2008-02-28 | 충남대학교산학협력단 | Piglet production method by simultaneous transfer of embryos formed by in vitro fertilization and nuclear transfer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dowling | Problems of the transplantation of fertilized ova | |
AU739902B2 (en) | Efficient nuclear transfer using fetal fibroblasts | |
CN101492669B (en) | Method for cloning embryo with cattle spermatozoon | |
KR100807644B1 (en) | Piglet production method by simultaneous transfer of embryos formed by in vitro fertilization and nuclear transfer | |
JP2010517563A (en) | Method for improving production efficiency of somatic cell nuclear transfer offspring in canines | |
Vijayalakshmy et al. | Embryo transfer technology in animals: An overview | |
WO2001096533A1 (en) | Monkey-origin embryonic stem cells | |
KR20050034187A (en) | Method of efficient surgical transfer of porcine nuclear transfer embryos | |
KR100479704B1 (en) | Method of producing a transgenic pig expressing green fluorescent protein | |
KR101763343B1 (en) | Method for Producing Cloned Canidae Using Nuclear Transfer of Somatic Cells or Stem Cells | |
CN113736728A (en) | Mouse somatic cell nuclear transfer embryo culture solution and embryo culture method | |
KR101046706B1 (en) | Straw Embryos Implantation in Mammals | |
KR100500412B1 (en) | Method for production of cloned animal embryos by nuclear transfer | |
Mullins et al. | Transgenesis in the rat | |
John Clark | Generation of transgenic livestock by pronuclear injection | |
CN100526456C (en) | Method for transplanting consubstantial cell nucleus | |
NZ543720A (en) | Method for cloning of the rat by nuclear transfer | |
KR20100081805A (en) | Method for producing cloned canidae using nuclear transfer of somatic cells or stem cells | |
KR101939570B1 (en) | a production method of a cloned dog and the dog using thereof | |
KR20090115081A (en) | Cloning Method Of Canids | |
JP2008173113A (en) | Method for producing cloned dog | |
Galli et al. | Achievements of research in the field of Reproduction Science | |
KR100502480B1 (en) | Method of producing porcine clonal somatic cell line expressing green fluorescent protein | |
KR101943158B1 (en) | a production method of a cloned dog and the dog using thereof | |
Lian et al. | Application status of genome-editing tools in sheep and goats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
J501 | Disposition of invalidation of trial |